<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315133</url>
  </required_header>
  <id_info>
    <org_study_id>HCFMRPUSP</org_study_id>
    <nct_id>NCT00315133</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus</brief_title>
  <official_title>Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes Mellitus- a Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effect of inactivation of the immune system with chemotherapy and
      immunotherapy and infusion of bone marrow stem cells in early onset type 1 diabetes mellitus.
      We hypothesize that reprograming the immune system will stop immune aggression to the insulin
      producing cells allowing their regeneration and thus decreasing or eliminating the need of
      exogenous insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from 12 to 35 years old with type I diabetes mellitus proved by anti-pancreatic beta
      cell antibodies and recently diagnosed (less than 6 weeks) will be included in this study.
      Peripheral blood hematopoietic stem cells will be mobilized from bone marrow of the patient
      with cyclophosphamide plus G-CSF (granulocyte-colony stimulating factor), collected by
      leukapheresis and cryopreserved. After 2-3 weeks, high dose immunosuppression is given
      (cyclophosphamide 200 mg/kg plus rabbit antithymocyte globulin 4.5 mg/kg) and stem cells are
      thawed and injected intravenously. This procedure is performed in isolated rooms at the Bone
      Marrow Transplantation Unit of the School of Medicine of Ribeirão Preto, University of São
      Paulo, Brazil. Patients are discharged from the hospital after engraftment and closely
      followed up to 2 months after transplantation (with at least weekly outpatient visits) and
      continue the followup for 5 years after transplantation. Clinical, hematological, metabolical
      and immunological evaluations are performed to analyse the effect of the transplant in the
      disease and in the hematopoetic and immunologic systems of the body. Patients fitting the
      inclusion criteria but not agreeing to perform the transplantation are the control group and
      they will be followed in parallel with transplanted patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide levels</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Stimulated C-peptide levels will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant-related toxicity</measure>
    <time_frame>Every 6 months or when reported</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-GAD titres</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin dose</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Number of international insulin units per kilogram per day in use will be registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>Every 6 months</time_frame>
    <description>Hb A1C will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic reconstitution parameters</measure>
    <time_frame>Yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Every year</time_frame>
    <description>SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Transplant arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunosuppression and autologous stem cell transplantation</intervention_name>
    <description>Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).</description>
    <arm_group_label>Transplant arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus diagnosed by clinical/metabolic parameters and positive
             anti-GAD antibodies

          -  Less than 12 weeks from diagnosis

        Exclusion Criteria:

          -  Previous diabetic ketoacidosis

          -  Pregnancy

          -  Severe psychiatric disorder

          -  Severe organic impairment (renal, hepatic, cardiac, pulmonary)

          -  Active infectious disease

          -  Previous or present neoplastic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio C Voltarelli, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, School of Medicine of Ribeirão Preto, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria C Oliveira, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Ribeirão Preto Medical School, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.hcrp.fmrp.usp.br</url>
    <description>General information about the institution where the trial is conducted</description>
  </link>
  <link>
    <url>http://lgmb.fmrp.usp.br/inctc</url>
    <description>General information about the blood and research center where stem cells are collected and where immunologic studies are performed</description>
  </link>
  <reference>
    <citation>Burt RK, Oyama Y, Traynor A, Kenyon NS. Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis. Autoimmun Rev. 2002 May;1(3):133-8. Review.</citation>
    <PMID>12849006</PMID>
  </reference>
  <results_reference>
    <citation>Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simões BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007 Apr 11;297(14):1568-76.</citation>
    <PMID>17426276</PMID>
  </results_reference>
  <results_reference>
    <citation>Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1573-9. doi: 10.1001/jama.2009.470.</citation>
    <PMID>19366777</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Julio C. Voltarelli</investigator_full_name>
    <investigator_title>Julio C. Voltarelli</investigator_title>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Autoimmune diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD may be shared if the responsible investigators feel it may increase understanding, reliability and reproducibility of the present study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

